Puma set for gap down at the open

|About: Puma Biotechnology, Inc. (PBYI)|By:, SA News Editor

Puma Biotechnology (NYSE:PBYI) is off 10% premarket on modest volume (~10K shares). Yesterday, it reported results from a Phase 2 study of neratinib for the treatment of breast cancer. Its therapeutic effect was similar to Herceptin (both administered with paclitaxel).

Previously: Puma Biotech cancer drug candidate similar to Herceptin in Phase 2 trial

Subscribe for full text news in your inbox